ClinicalTrials.gg
RecruitingNCT07297212Updated Oct 28, 2026

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

A Phase 2 interventional study of Pumitamig and Bevacizumab in Recurrent Glioblastoma, sponsored by BioNTech SE. Recruiting at 6 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by BioNTech SE · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 28, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Glioblastoma with a site in China — 73 open to participants now, 80 under way, 7 of them phase 3. Glioblastoma · China.

Planned enrollment
35th of 127
75 · median 36
Started
2026
with 19 others
Phase 2
35 of 142
17 open now
Primary completion
2028-01
later than 60 of 79 live
Registered
118th of 142
by date

Among the 142 studies in Glioblastoma with a site in China, this one is the 35th largest by planned enrollment of the 127 interventional ones that give a count, is one of 20 that started in 2026, is one of 35 in phase 2, reaches primary completion later than 60 of the 79 other live ones, and was the 118th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

73 of the 142 studies in Glioblastoma with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 73 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Glioblastoma with a site in China, or all of them as a file.
02

Study summary

This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype consistent with WHO central nervous system (CNS) 2021 criteria who have received prior first-line treatment including with at least radiotherapy and temozolomide, with a Karnofsky performance status (KPS) ≥60, adequate organ function, and at least one measurable lesion according to the response assessment in neuro-oncology (RANO) 2.0 criteria.

Read the detailed description

Participants will be randomized to the two treatment Arms 1 and 2. After sponsor evaluation of the initial safety signals from Arm 1, it will be determined whether to initiate Arm 3. Participants who have disease progression in Arm 2 may be eligible to receive pumitamig.

There will be a screening period of up to 28 days, followed by a treatment period lasting up to 2 years. Participants will be followed-up for safety for up to 90 days after the last dose of study treatment or until the participant initiates new anticancer treatment (e.g., systemic, radiotherapy/surgery). Thereafter, survival follow-up will be conducted until the participant dies, the participant withdraws consent for survival status follow-up, loss of contact, or study termination (whichever occurs first).

03

Conditions studied

  • Recurrent Glioblastoma

Keywords

  • Bispecific antibody
  • Immunotherapy
  • Immunotherapy in combination with chemotherapy
  • Brain tumor
  • Programmed death-ligand 1 (PD-L1)
  • Vascular endothelial growth factor(-A) (VEGF-A)
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults, aged 18 to 75 years inclusive at the time of giving . Local laws will be followed in countries where adulthood is defined as older than 18 years.
  • Have a confirmed diagnosis of WHO Grade IV GBM, IDH-wildtype consistent with WHO CNS 2021 criteria.
  • Have recurrent supratentorial GBM who have received prior treatment with at least radiotherapy and temozolomide. Exception: For participants who discontinued temozolomide or switched to an alternative treatment prior to disease recurrence due to temozolomide intolerance, an interval of ≥6 months between the completion of radiotherapy and first disease recurrence is acceptable.
  • Have first recurrence documented by magnetic resonance imaging (MRI), with an interval of at least 12 weeks after the end of prior radiotherapy unless there is either: i) histopathologic confirmation of recurrent tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field.
  • Have been clinically evaluated as having or progressed disease with at least one as the targeted lesion based on RANO 2.0 criteria.
  • Have ≥60.
  • Can swallow the medication and maintain oral administration.
  • Have a baseline brain MRI, not more than 14 days before starting the study treatment.
  • Have a stable dose of ≥7 days before the contrast-enhanced scan.
  • Have adequate organ function, as defined in the protocol.

Key Exclusion Criteria:

  • Have received any of the following therapies or drugs before study enrollment:

    • Any anticancer therapies, including systemic, palliative, biologic, immunostimulatory, or treatment within 4 weeks (or five half-lives, whichever is longer) before starting the study treatment. For bevacizumab, the is 4 weeks before the first dose of study treatment.
    • Programmed death-1 / programmed death-ligand 1/vascular endothelial growth factor bispecific antibodies, cluster of differentiation 137 agonists or other immune checkpoint blockade therapies including monotherapy with either category or combinations thereof.
    • Systemic corticosteroids (at a dosage greater than 2 mg/day of dexamethasone or an equivalent dose of other corticosteroids) within 7 days before starting the study treatment.
    • Vaccinations with (s) within 4 weeks before starting the study treatment.
    • Broad-spectrum intravenous antibiotics therapy within 2 weeks before starting the study treatment.
    • Any non-study medicinal product within five half-lives of the first dose or within 4 weeks, whichever is longer, before starting the study treatment in this study or ongoing participation in the active treatment phase of another interventional clinical study.
    • Antiplatelet drugs, such as aspirin (>325 mg/day), clopidogrel (>75 mg/day), dipyridamole, ticlopidine or cilostazol, etc., within 10 days before starting the study treatment to avoid inclusion of participants who have used aggregation inhibitors before the study.
  • Have had more than one recurrence of GBM.
  • Are allergic to dacarbazine and temozolomide.
  • Have known , extracranial disease, or multicentric disease.
  • Have been diagnosed with secondary GBM (i.e., glioblastomas that progress from low grade diffuse astrocytoma or anaplastic astrocytoma).
  • Have previously received radiotherapy with anything other than standard radiotherapy (i.e., focally directed radiation).
  • Have received prior interstitial brachytherapy, interstitial thermal therapy, implanted chemotherapy, or therapeutics delivered by local injection or convection-enhanced drug delivery. Participants who had prior treatment with Gliadel® wafers and who had concurrent use of devices such as Tumor Treating Fields are excluded.
  • Have uncontrolled hypertension or poorly controlled diabetic conditions as specified in the protocol before study enrollment.
  • Are unable (due to existent medical condition, e.g., pacemaker or implantable cardioverter defibrillator device) or unwilling to have a head contrast-enhanced MRI.
  • Have undergone major surgery, open , or significant traumatic injury within 28 days before starting the study treatment, or a planned/anticipated need for major surgery during the study treatment period. Placement of vascular infusion devices is allowed. Note: If participant has had major surgery, they must have recovered adequately from the toxicity and/or complications from the treatment prior to the initiation of study treatment.
  • Have received hematopoietic stem cell transplantation or organ transplantation.
  • Have had other malignant tumors within 5 years before starting the study treatment. Exception: those who have been cured with local treatment (such as basal cell or squamous-cell carcinoma of the skin, superficial or noninvasive bladder cancer, carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, and papillary carcinoma of thyroid and early-stage prostate cancer).
  • Have any of the following heart conditions within 6 months before starting the study treatment:

    • Myocardial infarction, unstable angina, acute coronary syndrome, coronary artery bypass grafting, congestive heart failure, aortic dissection, stroke, cerebrovascular accident or other Grade 3 and above cardiovascular events.
    • functional classification ≥II heart failure or \<50%.
    • Ventricular arrhythmias requiring clinical intervention, second- to third-degree atrioventricular block, or congenital long syndrome. Participants with stable treated cardiac arrythmia/atrial fibrillation are allowed.
    • Mean QT interval corrected by Fridericia's method (QTcF) >480 ms (the can be repeated at the discretion of the investigator).
    • Cardiac troponin I or T >2 × upper limit normal.
  • Have serious or non-healing wounds, ulcers, or (incompletely healed) bone fracture. This includes history (within 6 months before starting the study treatment) or risk of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess or esophageal and gastric varices, or acute gastrointestinal bleeding. In addition, the participant must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing the fistula/perforation.
  • Have significant risk of hemorrhage (in the opinion of the investigator) or evidence of major coagulation disorders.
  • Have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). However, participants who are clinically stable following treatment for these conditions (including therapeutic thoracentesis or paracentesis or with indwelling catheters, e.g., PleurX) are allowed.
  • Have adverse events from prior antitumor therapy that have not returned to Grade 1 (graded by v5.0 criteria) or below (unless the investigator determines that certain adverse events pose no safety risk to participants, such as hair loss or stable hypothyroidism under hormone replacement therapy).
  • Active colitis, including infectious, radioactive, ischemic enteritis, within 4 weeks before starting the study treatment.
  • History of serious allergic diseases, history of serious allergy to drugs (including unlisted investigational drug) or known allergy or intolerance to any ingredient of the study treatment.
  • Uncontrolled seizures after best medical therapy or other neurological conditions including neurological disorders which can increase risk for adverse effects or confound assessment of study outcomes as determined by the investigator.
  • Have superior vena cava syndrome or symptoms of spinal cord compression.
  • Have active, or a history of, pneumonitis requiring treatment with steroids, or have active or a history of interstitial lung disease.
  • Have a known history of tuberculosis that was not successfully treated.

NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Arm 1: Pumitamig Monotherapy

    Drug: Pumitamig

  • Active comparator
    Arm 2: Bevacizumab Monotherapy

    Drug: Bevacizumab

  • Experimental
    Arm 3: Pumitamig + temozolomide

    Drug: Pumitamig · Drug: Temozolomide

Interventions

06

What researchers measure

Primary outcomes

  1. Confirmed overall response rate (ORR)

    For Treatment Arms 1 and 2 only. Defined as the percentage of study participants in whom a confirmed complete response (CR) or confirmed partial response (PR) (assessed by the blinded independent central review \[BICR\] per RANO 2.0) is observed as best overall response.

    Time frame: Up to 24 months

  2. Occurrence of treatment emergent adverse events (TEAEs) by severity

    According to (United States National Cancer Institute) Common Terminology Criteria for Adverse Events version 5.0 \[CTCAE v5.0\]). By relationship. For Treatment Arms 1 and 3 only.

    Time frame: From the first dose of study treatment until 90 days after the last dose of study treatment (up to 27 months)

  3. Occurrence of dose interruptions, reductions or discontinuations of study treatment due to TEAEs

    For Treatment Arms 1 and 3 only.

    Time frame: Up to 24 months

Secondary outcomes

  1. Confirmed ORR

    Defined as the percentage of study participants in whom a confirmed CR or confirmed PR (assessed per RANO 2.0) is observed as best overall response. For Treatment Arms 1 and 2, assessment will be done by the investigator. For Treatment Arm 3, assessment will be done only by BICR.

    Time frame: Up to 24 months

  2. Progression free survival (PFS)

    For Treatment Arms 1 and 2 only. Defined as the time from randomization to first documented tumor progression (progressive disease assessed by BICR and investigator per RANO 2.0) or death from any cause, whichever occurs first.

    Time frame: Up to 24 months

  3. PFS at 6 months

    For Treatment Arms 1 and 2 only. Assessed by BICR and investigator per RANO 2.0.

    Time frame: At 6 months from time of randomization

  4. Duration of response

    For Treatment Arms 1 and 2 only. Defined as the time from first objective response (CR or PR as assessed by BICR and investigator per RANO 2.0) to first occurrence of objective tumor progression (progressive disease as assessed by BICR and investigator per RANO 2.0), or death from any cause, whichever occurs first.

    Time frame: Up to 24 months

  5. Disease control rate

    For Treatment Arms 1 and 2 only. Defined as the percentage of study participants in whom a confirmed CR or confirmed PR or confirmed minor response or stable disease (assessed by BICR and investigator per RANO 2.0) is observed as best overall response.

    Time frame: Up to 24 months

  6. Overall survival (OS)

    For Treatment Arms 1 and 2 only. Defined as the time from participant randomization to death from any cause and at 6 and 12 months.

    Time frame: Up to 42 months

  7. OS rate

    For Treatment Arms 1 and 2 only.

    Time frame: At 6 and 12 months

  8. Pharmacokinetic (PK) assessment: Maximum concentration (Cmax) of pumitamig

    For Treatment Arms 1 and 3 only. As data permits.

    Time frame: From the first dose of study treatment until 90 days after the last dose of study treatment (up to 27 months)

  9. PK assessment: Minimum concentration (Cmin) of pumitamig

    For Treatment Arms 1 and 3 only. As data permits.

    Time frame: From the first dose of study treatment until 90 days after the last dose of study treatment (up to 27 months)

  10. The prevalence and incidence of anti-pumitamig antibodies

    For Treatment Arms 1 and 3 only. From before the first dose of study treatment until the last survival follow-up visit. Antidrug antibody (ADA) prevalence is the proportion of study participants with positive ADA against pumitamig at any point in time (baseline or post-baseline) during the study period. ADA incidence is the proportion of study participants with treatment-emergent ADA against pumitamig during the study period. Participants with treatment-emergent ADA includes study participants who were ADA negative or missing at baseline and became ADA positive post-baseline (treatment-induced ADA), and study participants who were ADA positive at baseline and post-baseline but had an increase in ADA titer of defined threshold from baseline to post-baseline (treatment-boosted ADA).

    Time frame: Up to 27 months

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2028, 24 months after the start.

Of 51 industry-sponsored phase 2 interventional studies under Glioblastoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 58. This study's planned 24 months is below that.

Counting every sponsor, half of 249 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 22, 2025
StartActual
Jan 15, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jul 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
5 criteria edited
What changed in the criteria
  • EditedAdults, aged 18- to 75 years inclusive at the time of giving informed consent. Local laws will be followed if the age at consentin countries where adulthood is defined as older than 18 years.
  • ChangedBefore Have recurrent supratentorial GBM who have received prior treatment with at least radiotherapy and temozolomide.Now Have recurrent supratentorial GBM who have received prior treatment with at least radiotherapy and temozolomide. Exception: For participants who discontinued temozolomide or switched to an alternative treatment prior to disease recurrence due to temozolomide intolerance, an interval of ≥6 months between the completion of radiotherapy and first disease recurrence is acceptable.
  • EditedAny anticancer therapies, including systemic, palliative, biologic, immunostimulatory, or immunosuppressive treatment within 4 weeks (or five half-lives, whichever is longer) before starting the study treatment. For bevacizumab, the washout period is 4 weeks before the first dose of study treatment.
  • EditedPD(L)Programmed death-1 /VEGF programmed death-ligand 1/vascular endothelial growth factor bispecific antibodies, cluster of differentiation (CD)137 agonists or other immune checkpoint blockade therapies including monotherapy with either category or combinations thereof.
  • EditedMean QT interval corrected by Fridericia's method (QTcF) >480 ms (the electrocardiogram can be repeated at the discretion of the investigator).
Oct 28, 2026
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionConfirmed ORR: how it is measured was reworded
  • DescriptionDisease control rate: how it is measured was reworded
  • DescriptionThe prevalence and incidence of anti-pumitamig antibodies: how it is measured was reworded
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Eligibility 5 criteria edited
    What changed in the criteria
    • EditedAdults, aged 18- to 75 years inclusive at the time of giving informed consent. Local laws will be followed if the age at consentin countries where adulthood is defined as older than 18 years.
    • ChangedBefore Have recurrent supratentorial GBM who have received prior treatment with at least radiotherapy and temozolomide.Now Have recurrent supratentorial GBM who have received prior treatment with at least radiotherapy and temozolomide. Exception: For participants who discontinued temozolomide or switched to an alternative treatment prior to disease recurrence due to temozolomide intolerance, an interval of ≥6 months between the completion of radiotherapy and first disease recurrence is acceptable.
    • EditedAny anticancer therapies, including systemic, palliative, biologic, immunostimulatory, or immunosuppressive treatment within 4 weeks (or five half-lives, whichever is longer) before starting the study treatment. For bevacizumab, the washout period is 4 weeks before the first dose of study treatment.
    • EditedPD(L)Programmed death-1 /VEGF programmed death-ligand 1/vascular endothelial growth factor bispecific antibodies, cluster of differentiation (CD)137 agonists or other immune checkpoint blockade therapies including monotherapy with either category or combinations thereof.
    • EditedMean QT interval corrected by Fridericia's method (QTcF) >480 ms (the electrocardiogram can be repeated at the discretion of the investigator).
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionConfirmed ORR: how it is measured was reworded
    • DescriptionDisease control rate: how it is measured was reworded
    • DescriptionThe prevalence and incidence of anti-pumitamig antibodies: how it is measured was reworded
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07297212
Lead sponsor
BioNTech SE
Collaborators
Bristol-Myers Squibb, BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
Jan 15, 2026
Primary completion
Jan 2028 (estimated)
Completion
Jul 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

BioNTech clinical trials patient information
Contact
patients@biontech.de
+49 6131 9084 ext. 0
BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion